JATT Acquisition (JATT) Competitors

$10.77 -0.18 (-1.61%)

Closing price 05/19/2026 03:54 PM Eastern

Extended Trading

$10.53 -0.24 (-2.26%)

As of 05/19/2026 05:29 PM Eastern

JATT vs. NAGE, PALI, CCCC, SLN, and ABEO

Should you buy JATT Acquisition stock or one of its competitors? MarketBeat compares JATT Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with JATT Acquisition include Niagen Bioscience (NAGE), Palisade Bio (PALI), C4 Therapeutics (CCCC), Silence Therapeutics (SLN), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry.

How does JATT Acquisition compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Niagen Bioscience has higher revenue and earnings than JATT Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

Niagen Bioscience presently has a consensus price target of $14.67, indicating a potential upside of 300.73%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Niagen Bioscience is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Niagen Bioscience has a net margin of 14.29% compared to JATT Acquisition's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
JATT Acquisition	N/A	-49.58%	2.84%

In the previous week, JATT Acquisition had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 2 mentions for JATT Acquisition and 1 mentions for Niagen Bioscience. JATT Acquisition's average media sentiment score of 0.00 beat Niagen Bioscience's score of -0.66 indicating that JATT Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Niagen Bioscience beats JATT Acquisition on 8 of the 12 factors compared between the two stocks.

How does JATT Acquisition compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

JATT Acquisition has lower revenue, but higher earnings than Palisade Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,256.72	-$16.78M	-$1.43	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Palisade Bio's return on equity of -36.79% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
JATT Acquisition	N/A	-49.58%	2.84%

Palisade Bio presently has a consensus price target of $10.20, indicating a potential upside of 463.54%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Palisade Bio had 9 more articles in the media than JATT Acquisition. MarketBeat recorded 11 mentions for Palisade Bio and 2 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.00 beat Palisade Bio's score of -0.97 indicating that JATT Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Palisade Bio beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.

How does JATT Acquisition compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, C4 Therapeutics had 9 more articles in the media than JATT Acquisition. MarketBeat recorded 11 mentions for C4 Therapeutics and 2 mentions for JATT Acquisition. C4 Therapeutics' average media sentiment score of 0.31 beat JATT Acquisition's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

JATT Acquisition has lower revenue, but higher earnings than C4 Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	9.57	-$104.99M	-$1.19	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

JATT Acquisition has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. JATT Acquisition's return on equity of -49.58% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
JATT Acquisition	N/A	-49.58%	2.84%

C4 Therapeutics presently has a consensus price target of $7.75, suggesting a potential upside of 149.20%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe C4 Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

C4 Therapeutics beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.

How does JATT Acquisition compare to Silence Therapeutics?

JATT Acquisition (NYSE:JATT) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

JATT Acquisition has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. JATT Acquisition's return on equity of -49.58% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Silence Therapeutics has a consensus price target of $55.00, suggesting a potential upside of 853.21%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Silence Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, JATT Acquisition had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for JATT Acquisition and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.80 beat JATT Acquisition's score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

JATT Acquisition has higher earnings, but lower revenue than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Silence Therapeutics	$560K	486.74	-$88.61M	-$1.59	N/A

Summary

Silence Therapeutics beats JATT Acquisition on 7 of the 13 factors compared between the two stocks.

How does JATT Acquisition compare to Abeona Therapeutics?

JATT Acquisition (NYSE:JATT) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Abeona Therapeutics has higher revenue and earnings than JATT Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Abeona Therapeutics	$5.82M	50.14	$71.18M	$0.97	5.28

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

JATT Acquisition's return on equity of -49.58% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 271.09%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Abeona Therapeutics had 17 more articles in the media than JATT Acquisition. MarketBeat recorded 19 mentions for Abeona Therapeutics and 2 mentions for JATT Acquisition. Abeona Therapeutics' average media sentiment score of 0.18 beat JATT Acquisition's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Abeona Therapeutics beats JATT Acquisition on 8 of the 11 factors compared between the two stocks.

Get JATT Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JATT vs. The Competition

Export

Metric	JATT Acquisition	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$85.45M	$308.28M	$6.25B	$22.83B
Dividend Yield	N/A	N/A	2.80%	4.11%
P/E Ratio	N/A	N/A	20.79	29.48
Price / Sales	N/A	187.72	531.21	23.83
Price / Cash	27.08	22.44	43.09	24.68
Price / Book	-20.33	4.68	9.81	4.61
Net Income	$6.85M	-$132.96M	$3.55B	$1.07B
7 Day Performance	0.22%	4.87%	-2.12%	-1.37%
1 Month Performance	5.11%	10.08%	-4.14%	-2.44%
1 Year Performance	897.59%	64.47%	28.34%	21.16%

JATT Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JATT JATT Acquisition	N/A	$10.77 -1.6%	N/A	+870.6%	$85.45M	N/A	N/A	3
NAGE Niagen Bioscience	3.6022 of 5 stars	$4.17 -0.5%	$15.00 +259.7%	-66.5%	$333.71M	$129.42M	19.86	120	High Trading Volume
PALI Palisade Bio	1.8132 of 5 stars	$1.80 -9.5%	$10.20 +466.7%	+163.0%	$333.17M	N/A	N/A	10	Earnings Report
CCCC C4 Therapeutics	1.8415 of 5 stars	$2.95 -1.0%	$7.75 +162.7%	+101.9%	$328.34M	$35.95M	N/A	150	Earnings Report
SLN Silence Therapeutics	2.6793 of 5 stars	$6.97 +0.3%	$55.00 +689.1%	+16.3%	$328.28M	$560K	N/A	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JATT) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

JATT Acquisition (JATT) Competitors

JATT vs. NAGE, PALI, CCCC, SLN, and ABEO

How does JATT Acquisition compare to Niagen Bioscience?

Summary

How does JATT Acquisition compare to Palisade Bio?

Summary

How does JATT Acquisition compare to C4 Therapeutics?

Summary

How does JATT Acquisition compare to Silence Therapeutics?

Summary

How does JATT Acquisition compare to Abeona Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

JATT Acquisition (JATT) Competitors

JATT vs. NAGE, PALI, CCCC, SLN, and ABEO

How does JATT Acquisition compare to Niagen Bioscience?

Do insiders and institutionals believe in NAGE or JATT?

Which has better valuation & earnings, NAGE or JATT?

Do analysts rate NAGE or JATT?

Is NAGE or JATT more profitable?

Does the media favor NAGE or JATT?

Summary

How does JATT Acquisition compare to Palisade Bio?

Which has preferable valuation and earnings, PALI or JATT?

Do institutionals and insiders believe in PALI or JATT?

Is PALI or JATT more profitable?

Do analysts rate PALI or JATT?

Does the media prefer PALI or JATT?

Summary

How does JATT Acquisition compare to C4 Therapeutics?

Does the media favor CCCC or JATT?

Do insiders & institutionals have more ownership in CCCC or JATT?

Which has stronger earnings & valuation, CCCC or JATT?

Is CCCC or JATT more profitable?

Do analysts prefer CCCC or JATT?

Summary

How does JATT Acquisition compare to Silence Therapeutics?

Is JATT or SLN more profitable?

Do analysts prefer JATT or SLN?

Do institutionals and insiders hold more shares of JATT or SLN?

Does the media favor JATT or SLN?

Which has preferable earnings and valuation, JATT or SLN?

Summary

How does JATT Acquisition compare to Abeona Therapeutics?

Which has preferable valuation & earnings, JATT or ABEO?

Do institutionals & insiders hold more shares of JATT or ABEO?

Is JATT or ABEO more profitable?

Do analysts rate JATT or ABEO?

Does the media prefer JATT or ABEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools